Skip to content

Study · Not a test of the peptide alone · 2025

6 results

Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.

Bardóczi A, Matics ZZ, Turan C, Szabó B, Molnár Z, Hegyi P, Müller V, Horváth G

Sleep medicine reviews17 Jun 2025Cited by 7 (Europe PMC)

PMID40633481 (opens in a new tab)DOI10.1016/j.smrv.2025.102119 (opens in a new tab)PepBankPUB-40633481
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Across incretin-based therapies including liraglutide in OSA studies, body weight and/or BMI were significantly reduced.

    In plain wordsAcross incretin therapies including liraglutide in OSA studies, body weight and/or BMI fell.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight and/or body mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.
    2 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    Across incretin-based therapies including tirzepatide in OSA studies, body weight and/or BMI were significantly reduced.

    In plain wordsAcross incretin therapies including tirzepatide in OSA studies, body weight and/or BMI fell.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight and/or body mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.
    2 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Across incretin-based therapies including liraglutide in OSA studies, apnea-hypopnea index decreased by a mean of -14.45 events/h (95% CI: 25.90 to -2.99; p < 0.001).

    In plain wordsAcross incretin therapies including liraglutide in OSA studies, sleep-apnea event frequency fell by 14.45 events/h on average.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Measurements

    Mean change
    −14.45 events/h
    pooled AHI
    Printed first 95% CI endpoint
    25.9 events/h
    as printed; source interval not reordered
    Printed second 95% CI endpoint
    −2.99 events/h
    as printed; source interval not reordered
    P-value
    < 0.001
    pooled AHI change

    Source sentences

    Summary
    Incretin-based therapies were also associated with AHI reduction, with a mean change of -14.45 events/h (95 % CI: 25.90 to -2.99, p < 0.001).
    3 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.
    Summary · context
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    Across incretin-based therapies including tirzepatide in OSA studies, apnea-hypopnea index decreased by a mean of -14.45 events/h (95% CI: 25.90 to -2.99; p < 0.001).

    In plain wordsAcross incretin therapies including tirzepatide in OSA studies, sleep-apnea event frequency fell by 14.45 events/h on average.

    Peptide
    Tirzepatide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Measurements

    Mean change
    −14.45 events/h
    pooled AHI
    Printed first 95% CI endpoint
    25.9 events/h
    as printed; source interval not reordered
    Printed second 95% CI endpoint
    −2.99 events/h
    as printed; source interval not reordered
    P-value
    < 0.001
    pooled AHI change

    Source sentences

    Summary
    Incretin-based therapies were also associated with AHI reduction, with a mean change of -14.45 events/h (95 % CI: 25.90 to -2.99, p < 0.001).
    3 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.
    Summary · context
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Across pooled incretin-based therapies including liraglutide in five OSA RCTs, apnea-hypopnea index was lower than with usual care (MD: -11.61 events/h; 95% CI: 22.91 to -0.31; p = 0.046).

    In plain wordsAcross pooled incretin therapies including liraglutide in five OSA trials, sleep-apnea event frequency was lower than with usual care.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Comparator
    Usual care
    Outcome group
    Sleep · Sleep

    Measurements

    Mean difference
    −11.61 events/h
    pooled therapies versus usual care
    Printed first 95% CI endpoint
    22.91 events/h
    as printed; source interval not reordered
    Printed second 95% CI endpoint
    −0.31 events/h
    as printed; source interval not reordered
    P-value
    0.046
    AHI versus usual care

    Source sentences

    Summary
    By pooling data of 5 RCTs in a pairwise meta-analysis, incretin-based therapies showed a greater effect on AHI than usual care, with a mean difference of -11.61 events/h (95 % CI: 22.91 to -0.31, p = 0.046).
    3 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.
    Summary · context
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    Across pooled incretin-based therapies including tirzepatide in five OSA RCTs, apnea-hypopnea index was lower than with usual care (MD: -11.61 events/h; 95% CI: 22.91 to -0.31; p = 0.046).

    In plain wordsAcross pooled incretin therapies including tirzepatide in five OSA trials, sleep-apnea event frequency was lower than with usual care.

    Peptide
    Tirzepatide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Comparator
    Usual care
    Outcome group
    Sleep · Sleep

    Measurements

    Mean difference
    −11.61 events/h
    pooled therapies versus usual care
    Printed first 95% CI endpoint
    22.91 events/h
    as printed; source interval not reordered
    Printed second 95% CI endpoint
    −0.31 events/h
    as printed; source interval not reordered
    P-value
    0.046
    AHI versus usual care

    Source sentences

    Summary
    By pooling data of 5 RCTs in a pairwise meta-analysis, incretin-based therapies showed a greater effect on AHI than usual care, with a mean difference of -11.61 events/h (95 % CI: 22.91 to -0.31, p = 0.046).
    3 context sentences
    Summary · context
    To investigate their efficacy in OSA, we performed a systematic literature search following PRISMA and Cochrane Handbook guidelines for studies reporting apnea-hypopnea index (AHI) and incretin-based therapy in patients with OSA.
    Summary · context
    Only randomized controlled trials were eligible for inclusion.
    Summary · context
    Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.